James Montier is one ofthe world's most famous value investors, says Finanz und Wirtschaft. So it's no surprise that his mainworry for now is that many stockmarkets are "revoltingly expensive".
Montier made his name as an investment strategist alongsideAlbert Edwards at Socit Gnrale,and is also an expert in behavioural finance. He is currently working for GMO, the investment management group.
The US market is practically in bubble territory, Montier says. Europe looks cheaper, but even there the periphery is no longer compelling value. There are pockets of excellent value in emerging markets, but the reason these pockets are so cheap is that they're "terrifying".
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
One is Chinese banks, which he daren't scoop up, given the scope for loans to turn bad. Russian energy stocks, on the other hand, he has been buying. They're ridiculously cheap, he says. Either the state will end up expropriating the shares, or they are worth a great deal more.
Korea is also worth a look. The government has been leaning on the chaebols, or big conglomerates, to up their dividends and ditch non-core businesses. The central bank may also take steps to weaken the currency, thus alleviating pressure on exporters beset by Japanese competition.
In general, however, Montier is content to keep 50% of his portfolio in cash and wait for setbacks on stockmarkets to throw up some bargains. As central banks have spent the past few years trying to blow up a new bubble, there should be plenty of those in the years ahead.
Andrew is the editor of MoneyWeek magazine. He grew up in Vienna and studied at the University of St Andrews, where he gained a first-class MA in geography & international relations.
After graduating he began to contribute to the foreign page of The Week and soon afterwards joined MoneyWeek at its inception in October 2000. He helped Merryn Somerset Webb establish it as Britain’s best-selling financial magazine, contributing to every section of the publication and specialising in macroeconomics and stockmarkets, before going part-time.
His freelance projects have included a 2009 relaunch of The Pharma Letter, where he covered corporate news and political developments in the German pharmaceuticals market for two years, and a multiyear stint as deputy editor of the Barclays account at Redwood, a marketing agency.
Andrew has been editing MoneyWeek since 2018, and continues to specialise in investment and news in German-speaking countries owing to his fluent command of the language.
In the doghouse: hundreds of investment funds are underperforming - is it time to sell?
News The latest Spot The Dog research from Bestinvest reveals 151 funds are failing to beat their benchmark. We reveal the worst performers
By Marc Shoffman Published
Nationwide: House prices creep up for the first time in over a year
Nationwide’s latest house price index reveals property prices are finally rising. Will this pattern continue in 2024?
By Vaishali Varu Published